Literature DB >> 10665787

Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome.

D M Brizel1, R K Dodge, R W Clough, M W Dewhirst.   

Abstract

BACKGROUND AND
PURPOSE: To evaluate the long term clinical significance of tumor oxygenation in a population of head and neck cancer patients receiving radiotherapy and to assess changes in tumor oxygenation during the course of treatment. METHODS AND MATERIALS: Patients with head and neck cancer receiving primary RT underwent pretreatment polarographic tumor oxygen measurement of the primary site or a metastatic neck lymph node. Treatment consisted of once daily (2 Gy/fraction to a total dose of 66-70 Gy) or twice daily irradiation (1.25 Gy/fraction to 70-75 Gy) to the primary site. Twenty-seven patients underwent a second series of measurements early in the course of irradiation.
RESULTS: Sixty-three patients underwent pretreatment tumor oxygen assessment (primary site, n = 24; nodes, n = 39). The median pO2 for primary lesions was 4.8 mmHg, and it was 4.3 mmHg for cervical nodes. There was a weak association between anemia and more poorly oxygened tumors, but many non-anemic patients still had poorly oxygenated tumors. Repeat assessments of tumor oxygenation after 10-15 Gy were unchanged compared to pretreatment baselines. Poorly oxygenated nodes pretreatment were more likely to contain viable residual disease at post-radiation neck dissection. Median follow-up time for surviving patients was 20 months (range 3-50 months). Hypoxia (tumor median pO2 <10 mmHg) adversely affected 2 year local-regional control (30 vs. 73%, P = 0.01), disease-free survival (26 vs. 73%, P = 0.005), and survival (35 vs. 83%, P = 0.02).
CONCLUSION: Tumor oxygenation affects the prognosis of head and neck cancer independently of other known prognostic variables. This parameter may be a useful tool for the selection of patients for investigational treatment strategies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10665787     DOI: 10.1016/s0167-8140(99)00102-4

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  126 in total

1.  Modeling pO(2) distributions in the bone marrow hematopoietic compartment. I. Krogh's model.

Authors:  D C Chow; L A Wenning; W M Miller; E T Papoutsakis
Journal:  Biophys J       Date:  2001-08       Impact factor: 4.033

2.  DLK1, delta-like 1 homolog (Drosophila), regulates tumor cell differentiation in vivo.

Authors:  Asma Begum; Yuri Kim; Qun Lin; Zhong Yun
Journal:  Cancer Lett       Date:  2011-12-03       Impact factor: 8.679

3.  In vivo observation of intracellular oximetry in perfluorocarbon-labeled glioma cells and chemotherapeutic response in the CNS using fluorine-19 MRI.

Authors:  Deepak K K Kadayakkara; Jelena M Janjic; Lisa K Pusateri; Won-Bin Young; Eric T Ahrens
Journal:  Magn Reson Med       Date:  2010-09-21       Impact factor: 4.668

4.  Low-field magnetic resonance imaging to visualize chronic and cycling hypoxia in tumor-bearing mice.

Authors:  Hironobu Yasui; Shingo Matsumoto; Nallathamby Devasahayam; Jeeva P Munasinghe; Rajani Choudhuri; Keita Saito; Sankaran Subramanian; James B Mitchell; Murali C Krishna
Journal:  Cancer Res       Date:  2010-07-20       Impact factor: 12.701

5.  Metastasis in melanoma xenografts is associated with tumor microvascular density rather than extent of hypoxia.

Authors:  Einar K Rofstad; Berit Mathiesen
Journal:  Neoplasia       Date:  2010-11       Impact factor: 5.715

Review 6.  Imaging tumor hypoxia to advance radiation oncology.

Authors:  Chen-Ting Lee; Mary-Keara Boss; Mark W Dewhirst
Journal:  Antioxid Redox Signal       Date:  2014-03-24       Impact factor: 8.401

Review 7.  Tumor Microenvironment in Head and Neck Squamous Cell Carcinomas.

Authors:  Görkem Eskiizmir
Journal:  Turk Arch Otorhinolaryngol       Date:  2015-09-01

Review 8.  Linking the history of radiation biology to the hallmarks of cancer.

Authors:  Mary-Keara Boss; Robert Bristow; Mark W Dewhirst
Journal:  Radiat Res       Date:  2014-05-08       Impact factor: 2.841

9.  The anti-protozoan drug nifurtimox preferentially inhibits clonogenic tumor cells under hypoxic conditions.

Authors:  Quhuan Li; Qun Lin; Hoon Kim; Zhong Yun
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

10.  Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases.

Authors:  Jacobus F A Jansen; Heiko Schöder; Nancy Y Lee; Ya Wang; David G Pfister; Matthew G Fury; Hilda E Stambuk; John L Humm; Jason A Koutcher; Amita Shukla-Dave
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-11-10       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.